# INTERNATIONAL AYURVEDIC MEDICAL JOURNAL



Research Article ISSN: 2320 5091 Impact Factor: 5.344

# CLINICAL EVALUATION OF THE EFFECT OF SHATPUSHPA KALPA IN STREE BANDHYATVA W.S.R. TO FEMALE INFERTILITY

Neeta Shelani<sup>1</sup>, Pravesh Tomar<sup>2</sup>

<sup>1</sup>PG Scholar, <sup>2</sup>Professor,

Dept. of Prasuti Tantra & Striroga, Rishikul Campus, Haridwar, UAU, Dehradun, Uttarkhand, India

Email: neetashelani93@gmail.com

Published online: September, 2019

© International Ayurvedic Medical Journal, India 2019

#### **ABSTRACT**

Female infertility is the major disorder which has altered the mankind for lack of conception and reproductively. Stressful work, excess radiation, lack of biological food, genetic disorder, changing life style, has result the female infertility. In *Ayurveda* text like *Charaka Samhita, Sushruth Samhita, Ras Ratna Samuchya, & Haritt Samhita,* so many type of *Bandhyatva* had described. *Acharya Sushruta* described four essential factors for conception i.e. *Ritu, Kshetra, Ambu,* and *Beeja.* In present study all the factor is taken up for clinical drug trial. *Acharya Kashyapa* described *Shatpushpa* in a separate chapter called "*Shatapushpa Shatavari Kalpadhyaya*" as nectar for woman in various female disorders i.e. infertility. *Bandhyatva* occurred by *Vata* vitiation The selected drug is effective due to *Vata Shamaka Guna. Shatapushpa* is the single drug of choice which is helpful in female reproductive disorders.

Keywords: Bandhyatwa, Ritu, Kshetra, Ambu, Beeja, Shatpusha kalpa

### INTRODUCTION

The God has blessed the female with most valuable gift of motherhood mother is also called as "*Janani*" who give birth to child. A woman hood is never considered complete without achievement of motherhood. *Acharya Charaka* has mentioned that the woman is the Cause of origin of progeny<sup>1</sup>

Bandhyatva (Infertility) is recognized since from Vedic period. The first systemic literature of health science Ayurveda has given detailed description in a classified manner.

Ritu (fertile period), Kshetra (Healthy uterus and female genital tract), Ambu (Nutritional fluid), Beeja

(high quality spermatozoa and high quality ovum) are essential factor for conception<sup>2</sup>, also healthy psychological status, normal functioning of *Vata* (one of the governing factors of body according to Ayurveda) and *Shadbhava* (six factors- *matru*, *pitru*, *atma*, *satva*, *satmya*, *rasa*). Any abnormality in these factors would cause infertility.<sup>3</sup>

In Ayurveda Acharya Sushruta used term Vandhya in Yoni vyapad<sup>4</sup> characterized by a specific feature, the Nashtartava & Acharya Charaka describe Vandhya under Beejanshdushti <sup>5</sup>

Acharya Sushruta has include Bandhyatva under the clinical feature of injury to Artavaha Srotas along with other symptoms i.e. dyspareunia and amenorrhoea. And Kashyapa described Bandhyatva in eighty type of vata disorder.

Infertility is a social stigma and ceasing the opportunity to procreate. Infertility is defined as the inability to conceive a pregnancy after one year of unprotected intercourse. It can either be primary where no previous pregnancy has occurred or secondary where there has been a previous documented pregnancy. In recent years, prevalence of Infertility has dramatically increased up to estimated 10 %- 15% of couple of reproductive age. In which female is directly responsible in 40-55 % of cases. 8

#### AIM AND OBJECTIVES

- ➤ To study the *Bandhyatva* in *Ayurveda* classics and infertility in Modern text books.
- To see the efficacy of Shatpusha kalpa in Bandhyatva.

#### M ATERIAL AND METHOD-

Total 30 Patients Diagnosed with will be selected by simple randomized method for the study within a single group attending Prasuti Tantra and Streerogas O.P.D. of Rishikul Ayurveda collage and hospital, Haridwar.

#### PLAN OF STUDY-

## 1) CRITERIA FOR SELECTION OF PATIENTS: A) INCLUSION CRITERIA

- 1. Married female patient with reproductive age (Age group 20-40).
- 2. Patient having complained of failure to conceive after 1 yr. of regular unprotected coitus.
- 3. Primary and secondary both type of infertile patient will be selected randomly.
- 4. Patient fulfilling the diagnostic criteria.

#### **B) EXCLUSION CRITERIA**

- 1. Abnormal semen analysis of male partner.
- 2. Patient suffering from acute and chronic medical and systemic diseases like Hypertension, T.B., Heart disease, Hypothyroidism, Hyperthyroidism, Patient having congenital anomalies of uterus i.e. Unicornuate uterus, Uterus didelphys, Bicornuate uterus, Septate uterus, arcuate uterus etc.

- 3. Patient having Pelvic diseases such as fibroids, benign/malignant tumours of ovary, STDs, PID, Endometriosis, cervicitis, Salpingitis etc.
- C) DIAGNOSTIC CRITERIA- Diagnosis will be made on the basis of following criteria
- 1. Detailed history according to Performa, *Prakriti Parikshana* and general, systematic gynaecological examination.
- 2. Patient having proper developed Secondary sexual characters like breast fully developed hair distribution on axillary & pubis and normal hair growth.
- 3. On P/S examination patient having normal vaginal canal with no infection and lesion.
- 4. On P/V examination patient having position of uterus either AV or RV, normal size of uterus, mobility of uterus i.e. mobile and clear Fornices.

#### ASSESSMENT CRITERIA-

- 1-Duration of menstrual flow
- 2- Amount of menstrual blood loss.
- 3- Interval of menstrual cycles.
- 4- Pain during menstrual cycles

#### **STUDY DESIGN: -**

**PERIOD OF STUDY:** for three consecutive menstrual cycles and one cycle after Completion of treatment.

**OBSERVATION:** Observation will be carried out before, during & after the treatment. The patients will be observed at 15 days' interval for assessment of parameters for three consecutive cycles in which drug will be given.

#### Type of Study: Open trial.

# PREPARATION OF SHATPUSHPA KALPA POWDER-

The drug Shatpushpa fruit in the form of Churna has classical references of Kashyapa Samhita in Bandhyatva, Artva Kshya (Hypomenorrhoea) and Kashtartva (Dysmenorrhoea) with Anupana of Gau-Ghrita (cow ghee). Manufacturing of the drug was completed in the pharmacy of Premnagar Ashram Haridwar, as per guidance and in presence of Research scholar. After proper identification, Shatpushpa fruit will be taken and powdered by the

help of mortar and pastel and then this powder was kept in air tight polybag for clinical trial.

# *Kalpa* schedule used in the present study was as follows:

According to *Kashaypa* Hundred *Pala* powder of *Shatpushpa* should be stored in new earthen pot. After getting up in the morning (of previously taken meal), according to the capacity of patients 1/4 *Pala*, 1/2 *Pala* or 1 *Pala* of this powder should be licked with

Gau-Ghrita. After its digestion the patient should eat cooked rice mixed with milk. After using hundred Pala of Shatpusha Kalpa the patient will conceive.

- Total 45 days increasing manner of dose -2400gm
- Next 45 days decreasing manner of dose -2400gm
- So the 90 days' period of study total *Kalpa* dose 4800gm {100 Pala}

#### SHATPUSHPA KALPA DOSE SCHEDULE

Increasing manner of dose-

| DOSE  | MINIMUM DOSE | DAYS           | TOTAL DOSE |
|-------|--------------|----------------|------------|
| 12 gm | 6gm BD       | 5 days         | 60gm       |
| 24gm  | 12 gm BD     | 6days-11 days  | 144gm      |
| 36gm  | 18gm BD      | 6 Days-17 days | 216gm      |
| 48 gm | 24gmBD       | 6days-23 days  | 288gm      |
| 60gm  | 30gm BD      | 7days-30 days  | 420gm      |
| 72gm  | 36gm BD      | 7 days-37days  | 504gm      |
| 84 gm | 42 gm BD     | 8 days- 45days | 772gm      |

#### Decreasing manner of dose-

| DOSE  | MINIMUM DOSE | DAYS           | TOTAL DOSE |
|-------|--------------|----------------|------------|
| 84gm  | 42gm BD      | 8days-53 days  | 772gm      |
| 72gm  | 36gm BD      | 7days- 60days  | 504gm      |
| 60 gm | 30gm BD      | 7 days- 67days | 420gm      |
| 48gm  | 24gm BD      | 6 days-73days  | 288gm      |
| 36gm  | 18gm BD      | 6 days-79 days | 216gm      |
| 24gm  | 12gmBD       | 6 days-85days  | 144gm      |
| 12gm  | 6gm BD       | 5 Days-90days  | 84gm       |

#### **Duration** –

This *Kalpa* schedule occupied a period of 90 days. During this period 4800grams of *Shatpusha* powder was consumed by each patient.

**Follow up -** Evaluation will be done before treatment and after treatment.

# OBSERVATION-

#### **DEMOGRAPHY OF GENERAL PROFILE**

The study shows that out of total 30 patients, maximum patients belonged to age group 26-30 years (40%), and Hindu religion (70%), educated up to secondary (47.5%), belong to middle class (57%) maximum patients were housewives (70%), had mixed diet (77%), Mrudu kostha (67%), Mandagni

(35%), Vata-Kapha Prakruti (40%), had normal psychological status and sound sleep (80%). The obstetrical history of parity, 36.6% was secondary infertility patients and 63.3% patients were nulliparous. In obstetrical history of abortion, 20% of patients were having history of abortion. This show the Kshetra, Ambu, is the main causative factor for fertility. On observation of menstrual history maximum 80% Patients were having irregular menstrual history. 60% patient were having Scanty bleeding during menses, and (50%.) patients were having menstrual interval >56 days. Maximum 60% patients required oral analgesics during menstruation.

## **Observation Recorded During and After Treatment on Different Parameters**

**Table 1:** Observation of 30 patients based on interval of menstruation

| Interval of   |   | Before    | During treatr         | nent  |                       |      |                       |       | After tre | atment |
|---------------|---|-----------|-----------------------|-------|-----------------------|------|-----------------------|-------|-----------|--------|
| Menstruation  |   | Treatment |                       |       |                       |      |                       |       |           |        |
| No. of pt.    |   | %         | 1 <sup>st</sup> cycle | %     | 2 <sup>nd</sup> cycle | %    | 3 <sup>rd</sup> cycle | %     | No. of    | %      |
|               |   |           | (no.0f Pt)            |       | (No. of pt.)          |      | (no. of pt.)          |       | pt.       |        |
| (Grade 0) 30- | 4 | 13.3%     | 7                     | 23.3% | 15                    | 50%  | 20                    | 66.6% | 25        | 83.3%  |
| 35 days       |   |           |                       |       |                       |      |                       |       |           |        |
| (Grade 1) 36- | 4 | 13.3%     | 5                     | 16.6% | 5                     | 16.6 | 4                     | 13.3% | 4         | 13.3%  |
| 45 days       |   |           |                       |       |                       | %    |                       |       |           |        |
| (Grade 2) 46- | 7 | 23.3%     | 8                     | 26.6% | 8                     | 26.6 | 5                     | 16.6% | 1         | 3.3%   |
| 55 days       |   |           |                       |       |                       | %    |                       |       |           |        |
| (Grade 3) >56 | 1 | 50%       | 10                    | 33.3% | 2                     | 6.6% | 1                     | 3.3%  | 0         | 0%     |
| days          | 5 |           |                       |       |                       |      |                       |       |           |        |

**Table 2:** Observation of 30 patients based on duration of menstruation

| <b>Duration of</b> | Before tr | eatment | During trea           | tment |                       |     |                       |       | After |       |  |
|--------------------|-----------|---------|-----------------------|-------|-----------------------|-----|-----------------------|-------|-------|-------|--|
| Menstruation       |           |         |                       |       |                       |     |                       |       |       |       |  |
|                    | No.of.pt  | %       | 1 <sup>st</sup> cycle | %     | 2 <sup>nd</sup> cycle | %   | 3 <sup>rd</sup> cycle | %     | N0.Of | %     |  |
|                    |           |         | (no. of pt.)          |       | (no. of pt.)          |     | (no.0f pt.)           |       | pt.   |       |  |
| (Grade 0)3-5       | 5         | 16.6%   | 7                     | 23.3% | 12                    | 40% | 20                    | 66.6% | 25    | 83.3% |  |
| days               |           |         |                       |       |                       |     |                       |       |       |       |  |
| (Grade 1)2         | 7         | 23.3%   | 10                    | 33.3% | 12                    | 40% | 5                     | 16.6% | 5     | 16.6% |  |
| days               |           |         |                       |       |                       |     |                       |       |       |       |  |
| (Grade 2) 1        | 11        | 36.6%%  | 8                     | 26.6% | 3                     | 10% | 5                     | 16.6% | 0     | 0%    |  |
| day                |           |         |                       |       |                       |     |                       |       |       |       |  |
| (Grade3)           | 7         | 23.3%   | 5                     | 16.6% | 3                     | 10% | 0                     | 0%    | 0     | 0%    |  |
| Spotting only      |           |         |                       |       |                       |     |                       |       |       |       |  |
| for1 day           |           |         |                       |       |                       |     |                       |       |       |       |  |

Table 3: Observation of 30 patients based on quantity of bleeding

| Quantity   | of      | Before  |       | During trea           | tment |                       |       |                         |       | After  |       |
|------------|---------|---------|-------|-----------------------|-------|-----------------------|-------|-------------------------|-------|--------|-------|
| bleeding   |         | treatme | ent   |                       |       |                       |       |                         |       |        |       |
|            |         | No. of  | %     | 1 <sup>st</sup> cycle | %     | 2 <sup>nd</sup> cycle | %     | 3 <sup>rd</sup> cycle ( | %     | N0.    | %     |
|            |         | pt.     |       | (no. of pt.)          |       | (no. of pt.)          |       | no.0f pt.)              |       | of pt. |       |
| (Grade     | 0)3-5   | 10      | 33.3% | 10                    | 33.3% | 17                    | 56.6% | 24                      | 80%   | 25     | 83.3% |
| pad/day    |         |         |       |                       |       |                       |       |                         |       |        |       |
| (Grade     | 1)2     | 10      | 33.3% | 11                    | 36.6% | 11                    | 36.6% | 5                       | 16.6% | 4      | 13.3% |
| pad/day    |         |         |       |                       |       |                       |       |                         |       |        |       |
| (Grade     | 2) 1    | 5       | 16.6% | 4                     | 13.3% | 1                     | 3.3%  | 1                       | 3.3%% | 1      | 3.3%  |
| pad/day    |         |         |       |                       |       |                       |       |                         |       |        |       |
| (Grade3)   | No pad  | 5       | 16.6% | 5                     | 16.6% | 1                     | 3.3%  | 0                       | 0%    | 0      | 0%    |
| use Spotti | ng only |         |       |                       |       |                       |       |                         |       |        |       |

 Table 4: Observation of 30 Patient Based on Pain Associated With Menstruation

| Pain associated with | Before   |      | Dur             | ing treat | ment  |                 |        |     |                 |         |     | After  |      |
|----------------------|----------|------|-----------------|-----------|-------|-----------------|--------|-----|-----------------|---------|-----|--------|------|
| menstruation         | treatmen | t    |                 |           |       |                 |        |     |                 |         |     | Treatm | ent  |
|                      | No. of   | %    | 1 <sup>st</sup> | cycle     | %     | 2 <sup>nd</sup> | cycle  | %   | 3 <sup>rd</sup> | cycle   | %   | N0.    | %    |
|                      | pt.      |      | (no.            | of pt.)   |       | (no.            | of pt) |     | (no             | 0f pt.) |     | Of pt. |      |
| Grade 1) No pain     | 5        | 16.6 | 7               |           | 23.3% | 12              |        | 40% | 15              |         | 50% | 22     | 73.3 |
|                      |          | %    |                 |           |       |                 |        |     |                 |         |     |        | %    |
| (Grade 2) Bearable   | 7        | 23.3 | 9               |           | 30%   | 12              |        | 40% | 12              |         | 40% | 8      | 26.6 |
| pain                 |          | %    |                 |           |       |                 |        |     |                 |         |     |        | %    |
| (Grade 3)            | 18       | 60%  | 14              |           | 46.6% | 6               |        | 20% | 3               |         | 10% | 0      | 0%   |
| Requirement of oral  |          |      |                 |           |       |                 |        |     |                 |         |     |        |      |
| analgesics           |          |      |                 |           |       |                 |        |     |                 |         |     |        |      |

**Table 5:** Observation on Ovulation (Foliicular Size)

| Ovulation (follicular size)             | Before tr    | eatment | After treatment                     |        |
|---|--------------|---------|-------------------------------------|--------|
|   | No. of pt. % |         | No. of pt.                          | %      |
| (Grade 0) Rupture of follicle(Ovulation | 1            | 3.3%    | 19 out of 13 patients got pregnant. | 63.35% |
| (Grade 1) 18-23mm                       | 1            | 3.3%    | 7                                   | 23.3%  |
| (Grade 2) 10-17mm                       | 8            | 26.6%   | 2                                   | 6.6%   |
| (Grade 3) <10mm                         | 20           | 66.6%   | 2                                   | 6.6%   |

Table 6: Spinbarkeit test wise distribution of 30 patients of Bandhyatva

| Spinbarkeit test   | Before treatment |        | After treatment |       |  |
|--------------------|------------------|--------|-----------------|-------|--|
|                    | No. of pt.       | %      | No. of pt.      | %     |  |
| (Grade 0) >9cm     | 3                | 10%    | 22              | 73.3% |  |
| (Grade 1) 5 to 9cm | 12               | 40%    | 4               | 13.3% |  |
| (Grade 2) 1 to 4cm | 11               | 36.6%% | 4               | 13.3% |  |
| (Grade 3) <1 cm    | 4                | 13.3%  | 0               | 0%    |  |

Table 7- Hysterosalpingography (HSG) wise distribution of Bandhyatva Patients.

| Hysterosalpingography (HSG)                                 | Before treatment |       | After treatment |       |
|---|------------------|-------|-----------------|-------|
|   | No. of pt.       | %     | No. of pt.      | %     |
| Grade 0- both tube patent, free Spillage from both tubes.   | 12               | 40%   | 12              | 40%   |
| Grade 1- Dye inserts bilaterally But there is spillage from | 0                | 0%    | 0               | 6.6%  |
| Tube on delayed imaging                                     |                  |       |                 |       |
| Grade 2- blockage present on                                | 0                | 0%    | 0               | 23.3% |
| Either side of fallopian Tube.                              |                  |       |                 |       |
| Grade 3- both tubes are blocked                             | 2                | 6.6 % | 2               | 6.6 % |

Table 8: Observation of 30 Patient Based on Endometrial Thickness

| Endometrial     | Before t | reatment | During treatn         | During treatment |                       |       |                       |       |     |    |       |
|-----------------|----------|----------|-----------------------|------------------|-----------------------|-------|-----------------------|-------|-----|----|-------|
| thickness       | No. of   | %        | 1 <sup>st</sup> cycle | %                | 2 <sup>nd</sup> cycle | %     | 3 <sup>rd</sup> cycle | %     | N0. | of | %     |
|                 | pt.      |          | (no. of pt.)          |                  | (no. of pt.)          |       | (no.of pt.)           |       | pt. |    |       |
| (Grade0) >9mm   | 3        | 10%      | 5                     | 16.6%            | 10                    | 33.3% | 15                    | 50%   | 22  |    | 73.3% |
| (Grade 1) 8-7mm | 12       | 40%      | 10                    | 33.3%            | 8                     | 26.6% | 10                    | 33.3% | 8   |    | 26.6% |
| (Grade 2) 5-6mm | 5        | 16.6%    | 10                    | 33.3%            | 7                     | 23.3% | 3                     | 10%   | 0   |    | 0%    |
| (Grade 3) <5mm  | 5        | 16.6%    | 5                     | 16.6%            | 5                     | 16.6% | 2                     | 6.6%  | 0   |    | 0%    |

#### **RESULTS: -**

#### Statistical Analysis-

- The information collected on the basis of observation was analysed by using appropriate
- statistical test (Wilcoxon signed rank test) on subjective criteria to evaluate the significance at different level i.e. at 0.05, 0.01 and 0.001 levels.
- Paired 't' test was applied on Objective criteria.

Table 9: Effect of Shatpusha Kalpa powder on subjective parameter-

| SYMPTOMS                             | Mean  |       | Mean       | %      | W     | P       |
|--------------------------------------|-------|-------|------------|--------|-------|---------|
|                                      | BT    | AT    | DIFFERENCE | RELIEF | Value | Value   |
| 1-Interval of menstruation           | 2.100 | 0.167 | 1.933      | 92.38% | 351   | < 0.001 |
| 2-Duration of menstruation1          | 1.533 | 0.167 | 1.36       | 88.71% | 325   | < 0.001 |
| 3-Quantity of bleeding               | 1.167 | 0.200 | 0.96       | 82.26% | 210   | < 0.001 |
| 4-Pain association with menstruation | 2.433 | 1.267 | 1.166      | 68.2%  | 300   | < 0.001 |

Table 10: Effect of Shatpusha Kalpa powder on Objective parameter-

| TEST                    | Mean   |        | Mean       | %      | S.D.  | S.E.  | P       | 't'   |
|-------------------------|--------|--------|------------|--------|-------|-------|---------|-------|
| •                       | BT     | AT     | DIFFERENCE | RELIEF |       |       | Value   | Value |
| 1-Spinbarkeit test      | 5.307  | 8.427  | 3.120      | 58.79% | 2.678 | 0.489 | < 0.001 | 6.38  |
| 2-Ovulation profile     | 10.680 | 20.047 | 9.367      | 87.70% | 5.537 | 1.011 | < 0.001 | 9.266 |
| 3-Endometrium thickness | 6.817  | 10.233 | 3.417      | 50.12% | 1.875 | 0.342 | < 0.001 | 9.979 |
| 4-HSG                   | 2      | 2      | 0.0        | 0%     | 0.00  | 0.00  | 0.00    | 0     |

#### **DISCUSSION**

# **Subjective Parameter Discussion (Effect of Drug on Interval of Menstruation)-**

Statistically analysing the effect of treatment on interval of menstrual cycle shows highly significant (p<0.001) result. It may be due to *Amapachana*, *Srotoshodhana* and *Vata Shamaka* properties of *Shatpushpa Kalpa* because they have *Katu*, *Tikta Rasa*, *Laghu*, *Rukshna*, *Tikshna Guna*, *Ushna Virya* & *Katu Vipaka*. It also increases the *Agneya Guna* of *Pitta* which is responsible for *Artva* formation. And decrease the interval of menstruation. As we know *Artva* is *Agneya* enhance the formation of *Artva* & normalize the quantity & quality of *Artva*.

#### Effect of Drug on Pain during Menses-

Menstrual pain was improved by 68.2% which is statistically highly significant (p<0.001). It relieves dysmenorrhoea due to inhibition of prostaglandin production and antispasmodic action.

Due to *Ushna Virya* it inhibits the *Sheeta Guna* of *Vatadosha* and *Tikshna*, *Laghu guna* inhibit the *Picchila Guna* of *Kapha*. Due to *Ushna* and *Tikshna Guna*, it acts as *Rajah pravartaka*. So It has good effect on *Rajorodha & Yonishoola*.

#### Effect of Drug on Duration of Menses-

Effect on duration of menstruation was improved by 88.71% which is statically highly significant (p<0.001). Shatpushpa promote normal flow of menstrual blood, due to Ushna and Tikshna Guna it acts as production of Artava. Artava is an Updhatus, formed from Rasa within a month after proper metabolism of by its Dhatwagni and Bhutagni. It can be said that Agneya Guna of Pitta increases amount of Artva.

#### Effect of Drug on Quantity of Menstrual Bleeding-

Effect on quantity of bleeding was improved by 82.26% which is statistically highly significant (p<0.001) due to *Ushna Guna* it normalizes vitiated *Vata* after normalize the *Vata & Kapha Dosha, Ushna guna* of *Shatpushpa* promote normal flow of menstrual blood.

Shatpushpa powder Guna of Deepana, Pachna and Amadoshahara. So it regulates Jatharagni, Dhatavagni & Bhutagni which correct metabolism in formation of Dhatus & Updhatus (Artva).

# **Objective Parameter Discussion**

### (Effect of Drug on Follicular Study (Ovulation) -

Effect on ovulation profile was improved by 82.26% Patients. Spinbarkeit test was positive in these

patients, which is statistically highly significant (p<0.001).

This may because Due to property of *Katu Rasa* and *Ruksha*, *Tikshna Guna*, it removes the obstruction in *srotas* by *Kapha Vata Shamaka*, *Amapachan Guna* of the drug, as obstruction is cleared, Proper functioning of *Apana Vata*, and normal *Rajah Pravritti* and effect of the phytoestrogenic property it increases the amount of cervical mucus.

Guna of Shatpushpa is Ushna & Tikshna it stimulates the Artvaha srotas and Beejagranthi. By the stimulation of Beejagranthi (ovary), Follicles size was increase and lead to ovulation.

Effect of Drug on Thickness of Endometrium In Follicular Study-Effect On Endometrium thickness was improved by 50.12% which is statistically highly significant (p<0.001). It is experimented that it is a good uterine stimulant drug. It increased vascularity of endometrium, regeneration & proliferation of the endometrium.

Shatpushpa is a phytoestrogenic property. It acts in both high estrogenic& low estrogenic condition thus increases the endometrial thickness. Kashyapa described that its Madhura, Brimhana, Balya & Rasayana Properties, increase the thickness of endometrium and increase responsiveness of endometrium to bear conception.

#### Probable Mode of Action of Shatapushpa Powder-

There are many cause of female infertility but anovulation is the commonest cause of all. Patients with regular or irregular menstrual cycle suffer from anovulation and long term treatment with hormonal imbalance result from much untoward effect like weight gain.

Although drug Shatpusha is having Ushna Virya, Vatanulomaka and Vata Shamaka drug so especially it acts on Vata Pradhan Kati Pradesh and corrects the Apana Vata dushti which regulate the menstrual cycle. Due to Katu Vipaka it corrects the Dhatvagni and release the obstruction of nutrition of next Dhatus and finally Artava Upadhatu also which gets nutrition from its mother Dhatu i.e. Rasa Dhatu.

Ovaries contain receptors which receive hormone under the influence of hypothalamus and pituitary gland. The drug seems to stimulate these receptors which lead to enhance ovarian function and resulting in ovulatory cycles. *Shatpushpa* by virtue of phytoestrogenic property it increases endometrial thickness.

According to Rasapanchaka of Shatpushpa Rasadhatu Vridhikara and will remove Ama and will help in its proper functioning. Having Madhura Rasa, Katu Vipaka and Ushna Virya which is a rare quality found only in Shatapushpa so it has Kapha Nashaka property also and will clear all the channels by removing Margavrodha and due to Ushna Guna it normalizes vitiated Vata after normalize the Vata & Kapha Dosha, it increases vitality power of reproductive organ & prepare Kshetra for conception because Samanya kapha have an anabolic action on body.

By the Rasa, Guna, Virya, Vipaka and karma of Shatpushpa Powder, it clears the Strotosanga & stimulates the Srotas. It enters in the microchannel (Srotasa).

Thus making the proper function of *Dhatwagni* which regulated the menstrual cycle and ovulation occurs.

### Effect of Shatpushpa Drug Based On Conception-

Overall this study concludes that the *Shatpusha kalpa* treatment in the management of female infertility is highly effective. The treatment modalities can also be helpful for management of oligomenorrrhea, scanty menses and Anovulation. If we consider the factors of *Stri Bandhyatva* the drug is also seeming to be effective on *Kshetra* and *Ambu* i.e., endometrial receptivity and functional anatomical features of fallopian tubes.

#### CONCLUSION

- Dose of medicine depend on the status of Agnibala of the patient.
- Due to hot potency of medicine it was not possible in few patients (of different status of Agni- bala) to give increased dose of Shatpushpa Kalpa, which resulted in negative effect to patient such as early menses, nausea, vomiting.
- Stree Bandhyatva is a Vata Dosha dominant disease and here as per Ayurveda science it is known that without the Vata Dosha streerogas will not be noticed.

- Female infertility due to ovarian factor contributes about 40% cases. Which include anovulation, failure of follicle development and release of ovum.
- Thus it is concluded that *Shatpusha* Powder in *Kalpa* method as an oral medicine shows better result in regularizing menstruation and normalizing the ovarian dysfunction.

#### REFERENCES

- Charak Samhita of Agnivesh with elaborated Vidyotini Hindi commentary by pt Kashinath shastri & dr. gorakhnath chatuvedi, part 2, chikitsa sthan 30/5, published by chaukhamba bharati academy varansi, reprint 2006
- Ambikadutta Shastry, 'Ayurveda Tattva Sandipika' vyakhamba Sanskrit Sansthana, Varanasi Sushruta Samhita, Su.Sha-2/35
- Charaka Samhita By Prof. Ravidutt Tripathi, chaukhamba Sanskrit pratishthan, Delhi, Edition:-Reprint 2009
- Sushruta Samhita edited with Ayurved tattva sandipika hindi commentary by kaviraj ambika dutt shashtri, uttar tantra 38/10,11, published by chaukhambha Sanskrit sansthan, Varanasi, reprint edition-2007
- Charaka Samhita of agnivesh with elaborated charak Chandrika hindi commentary by dr. Brahmanand tripathi,sharer shtan 2/17, published by Chaukhambha subharati prakashan, Varanasi, reprint edition 2006
- Sushruta Samhita edited with ayurved tatva sandipika hindi commentary by kaviraj ambika dutta shashtri, Sharer sthan 9/12, published by chaukhamba Sanskrit sansthan, Varanasi, Reprint Edition- 2007
- Pandit Hemraj Sharma Kashyapa Samhita or Vriddajivakeeya Tantra, Varanasi Chaukhabma Sanskrit Sansthan, Uttarpradesh, tenth edition 2005, Sutra sthan, 29 Chapters.
- 8. http://www.medicalnewstoday.com/article/165748.php 6/3/2012

## Source of Support: Nil Conflict Of Interest: None Declared

How to cite this URL: Neeta Shelani & Pravesh Tomar: Clinical Evaluation Of The Effect Of Shatpushpa Kalpa In Stree Bandhyatva W.S.R. To Female Infertility. International Ayurvedic Medical Journal {online} 2019 {cited September, 2019}

Available from: http://www.iamj.in/posts/images/upload/1894 1901.pdf